Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Persistent Diabetic Neovascularization
NCT00606138Phase 2Completed
- Sponsor
- Rush University Medical Center
- Start
- Jan 2008
- Primary completion
- Oct 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Rush University Medical Center. Primary endpoints: Mean Percentage Change of the Area of Neovascularization at 6 months, Mean Percentage Change of Macular Edema at 6 months and 2 more. Started Jan 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT00606138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00606138.